Toll-like receptor-4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma

Toll-like receptor-4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma

Significance: This review provides current overview of the emerging role of innate immunity in driving fibrosis, and preventing its resolution, in scleroderma (systemic sclerosis, SSc). Understanding the mechanisms of dysregulated innate immunity in fibrosis and SSc will provide opportunities for th...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Bhattacharyya, S, Midwood, K, Yin, H, Varga, J
Format:	Journal article
Sprache:	English
Veröffentlicht:	Mary Ann Liebert, Inc. 2017

Ähnliche Einträge

Targeting Toll-like receptors in autoimmunity.
von: Midwood, K, et al.
Veröffentlicht: (2009)

Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis.
von: Monaco, C, et al.
Veröffentlicht: (2011)

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis
von: Swati Bhattacharyya, et al.
Veröffentlicht: (2018-10-01)

Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis.
von: Goh, F, et al.
Veröffentlicht: (2012)

Toll-Like Receptor Signaling and Liver Fibrosis
von: Tomonori Aoyama, et al.
Veröffentlicht: (2010-01-01)

Investigating the role of toll-Like receptors in models of arthritis
von: Piccinini, A, et al.
Veröffentlicht: (2016)

Toll-like receptor 9 mediated responses in cardiac fibroblasts.
von: Ingrid Kristine Ohm, et al.
Veröffentlicht: (2014-01-01)

Scleroderma and scleroderma-like syndromes
von: Katarzyna Romanowska-Próchnicka, et al.
Veröffentlicht: (2024-06-01)

Toll-Like Receptors in Liver Fibrosis: cellular crosstalk and mechanisms
von: Ling eYang, et al.
Veröffentlicht: (2012-05-01)

Toll-Like Receptor 4 Activation Prevents Rat Cardiac Fibroblast Death Induced by Simulated Ischemia/Reperfusion
von: Pablo Parra-Flores, et al.
Veröffentlicht: (2021-06-01)

Corrigendum: Scleroderma and Scleroderma-like syndromes
von: Katarzyna Romanowska-Próchnicka, et al.
Veröffentlicht: (2024-07-01)

Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis
von: Elizabeth F. Redente, et al.
Veröffentlicht: (2021-01-01)

Avian Toll-like receptor 3 isoforms and evaluation of Toll-like receptor 3–mediated immune responses using knockout quail fibroblast cells
von: Mahesh KC, et al.
Veröffentlicht: (2020-12-01)

Tenascin-C drives persistence of organ fibrosis
von: Swati Bhattacharyya, et al.
Veröffentlicht: (2016-06-01)

Cinnamaldehyde Treatment of Prostate Cancer-Associated Fibroblasts Prevents Their Inhibitory Effect on T Cells Through Toll-Like Receptor 4
von: Mei J, et al.
Veröffentlicht: (2020-08-01)

Toll-Like Receptors
von: Aycan Kundakcı, et al.
Veröffentlicht: (2012-08-01)

The transcriptional cofactor nab2 is induced by tgf-Beta and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma.
von: Swati Bhattacharyya, et al.
Veröffentlicht: (2009-10-01)

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
von: Yang Xun, et al.
Veröffentlicht: (2021-10-01)

Toll-like receptor 7 signaling drives IgA responses
von: Bessa, J, et al.
Veröffentlicht: (2007)

Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.
von: Leask, A, et al.
Veröffentlicht: (2005)

A unique mode of extracellular matrix mediated immunity: how tenascin-C activates toll-like receptor 4
von: Zuliani-Alvarez, L, et al.
Veröffentlicht: (2017)

Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.
von: Richard A Steinman, et al.
Veröffentlicht: (2012-01-01)

Toll-Like Receptor 3 in Liver Diseases
von: Shi Yin, et al.
Veröffentlicht: (2010-01-01)

Autoinmunidad y receptores tipo Toll = Autoimmunity and toll-like receptors
von: Ossa Giraldo, Ana Claudia, et al.
Veröffentlicht: (2012-07-01)

Toll-Like Receptors Drive Specific Patterns of Tolerance and Training on Restimulation of Macrophages
von: Suzanne K. Butcher, et al.
Veröffentlicht: (2018-05-01)

Toll-like receptor 4 deficiency in mice impairs venous thrombus resolution
von: Haixin Yuan, et al.
Veröffentlicht: (2023-05-01)

Toll-like receptors in atherosclerosis.
von: Falck-Hansen, M, et al.
Veröffentlicht: (2013)

Signaling by toll-like receptors /
von: Konat, Gregory W.
Veröffentlicht: (2008)

Toll-Like Receptors in Angiogenesis
von: Karsten Grote, et al.
Veröffentlicht: (2011-01-01)

Candida and Toll-Like Receptors
von: Şayeste Demirezen, et al.
Veröffentlicht: (2012-12-01)

Toll-like receptors and atherosclerosis
von: Jerko Barbić, et al.
Veröffentlicht: (2009-02-01)

Toll Like Receptors 4 and 2 Expression in the Bronchial Mucosa of Patients with Cystic Fibrosis
von: Hans-Peter Hauber, et al.
Veröffentlicht: (2005-01-01)

Toll-like receptor signaling and SIGIRR in renal fibrosis upon unilateral ureteral obstruction.
von: Veronika Skuginna, et al.
Veröffentlicht: (2011-01-01)

The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury.
von: Jaklien C Leemans, et al.
Veröffentlicht: (2009-01-01)

Toll-like receptor expression in pulmonary sensory neurons in the bleomycin-induced fibrosis model.
von: Won Jai Jung, et al.
Veröffentlicht: (2018-01-01)

Ubiquitination in Scleroderma Fibrosis and Its Treatment
von: Ying Long, et al.
Veröffentlicht: (2018-10-01)

EXPRESSION FEATURES OF TOLL-LIKE RECEPTOR 2 AND TOLL-LIKE RECEPTOR 4 IN CHILDREN WITH ASTHMA
von: L. V. Gankovskaya, et al.
Veröffentlicht: (2017-08-01)

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
von: Carlene Petes, et al.
Veröffentlicht: (2017-09-01)

A protective role for toll-like receptor 3 but not toll-like receptor 7 in intimal hyperplasia
von: Cole, J, et al.
Veröffentlicht: (2011)

Neuroinflammation Upregulated Neuronal Toll-Like Receptors 2 and 4 to Drive Synucleinopathy in Neurodegeneration
von: Lucia Yi-Ru Chung, et al.
Veröffentlicht: (2022-03-01)